AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of advanced RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of advanced RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody, in Phase I and Phase II clinical trials in squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company's preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AVEO
CUSIP05358810
Phone617-588-1960
Debt
Debt-to-Equity Ratio-0.36
Current Ratio1.16
Quick Ratio1.16
Price-To-Earnings
Trailing P/E Ratio-18.13
Forward P/E Ratio-11.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.58 million
Price / Sales45.54
Cash FlowN/A
Price / CashN/A
Book Value($0.34) per share
Price / Book-8.53
Profitability
EPS (Most Recent Fiscal Year)($0.16)
Net Income$-65,020,000.00
Net Margins-453.00%
Return on EquityN/A
Return on Assets-39.82%
Miscellaneous
Employees19
Outstanding Shares119,030,000
Market Cap$341.62 million
AVEO Pharmaceuticals (NASDAQ:AVEO) Frequently Asked Questions
What is AVEO Pharmaceuticals' stock symbol?
AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."
How were AVEO Pharmaceuticals' earnings last quarter?
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) posted its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.09. The biopharmaceutical company earned $0.43 million during the quarter, compared to analyst estimates of $1.35 million. View AVEO Pharmaceuticals' Earnings History.
When is AVEO Pharmaceuticals' next earnings date?
What price target have analysts set for AVEO?
3 analysts have issued 12-month price targets for AVEO Pharmaceuticals' stock. Their predictions range from $5.00 to $6.50. On average, they anticipate AVEO Pharmaceuticals' share price to reach $5.75 in the next year. This suggests a possible upside of 98.3% from the stock's current price. View Analyst Price Targets for AVEO Pharmaceuticals.
What is the consensus analysts' recommendation for AVEO Pharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVEO Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AVEO Pharmaceuticals.
Who are some of AVEO Pharmaceuticals' key competitors?
Some companies that are related to AVEO Pharmaceuticals include Kiniksa Pharmaceuticals (KNSA), Deciphera Pharmaceuticals (DCPH), Impax Laboratories (IPXL), ImmunoGen (IMGN), IMMURON Ltd/S (IMRN), Esperion Therapeutics (ESPR), Endocyte (ECYT), Omeros (OMER), Retrophin (RTRX), Viking Therapeutics (VKTX), Lexicon Pharmaceuticals (LXRX), Intra-Cellular Therapies (ITCI), Karyopharm Therapeutics (KPTI), Alder Biopharmaceuticals (ALDR) and Athenex (ATNX).
Who are AVEO Pharmaceuticals' key executives?
AVEO Pharmaceuticals' management team includes the folowing people:
- Mr. Michael P. Bailey, CEO, Pres & Director (Age 53)
- Mr. Matthew D. Dallas, Chief Financial Officer (Age 43)
- Dr. Michael N. Needle, Chief Medical Officer (Age 58)
- Dr. Nikhil Mehta Ph.D., Sr. VP of Regulatory & Quality Assurance (Age 59)
- Dr. Emile Farhan Ph.D., VP of Technical Operations
Has AVEO Pharmaceuticals been receiving favorable news coverage?
Press coverage about AVEO stock has trended somewhat positive on Thursday, according to Accern Sentiment. The research group identifies positive and negative press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AVEO Pharmaceuticals earned a news and rumor sentiment score of 0.18 on Accern's scale. They also gave media headlines about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future. View Recent Headlines for AVEO Pharmaceuticals.
Who are AVEO Pharmaceuticals' major shareholders?
AVEO Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include NEA Management Company LLC (14.95%), BlackRock Inc. (5.86%), Northern Trust Corp (0.92%), Bank of New York Mellon Corp (0.24%), Bank of New York Mellon Corp (0.24%) and Schwab Charles Investment Management Inc. (0.18%). Company insiders that own AVEO Pharmaceuticals stock include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Institutional Ownership Trends for AVEO Pharmaceuticals.
Which institutional investors are selling AVEO Pharmaceuticals stock?
Which institutional investors are buying AVEO Pharmaceuticals stock?
AVEO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., NEA Management Company LLC, Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Schwab Charles Investment Management Inc., Rhumbline Advisers and Creative Planning. Company insiders that have bought AVEO Pharmaceuticals stock in the last two years include Equity Opportunities Iv Growth, Peter J Barris and Ravi Viswanathan. View Insider Buying and Selling for AVEO Pharmaceuticals.
How do I buy shares of AVEO Pharmaceuticals?
Shares of AVEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is AVEO Pharmaceuticals' stock price today?
One share of AVEO stock can currently be purchased for approximately $2.90.
How big of a company is AVEO Pharmaceuticals?
AVEO Pharmaceuticals has a market capitalization of $341.62 million and generates $7.58 million in revenue each year. The biopharmaceutical company earns $-65,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. AVEO Pharmaceuticals employs 19 workers across the globe.
How can I contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals' mailing address is ONE BROADWAY 14TH FLOOR, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-588-1960 or via email at [email protected]
MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe AVEO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVEO will underperform the S&P 500 over the long term. You may vote once every thirty days.
